Clinical trial results:
Phase IIa, double-blind, randomized, placebo-controlled study of the efficacy and safety of SOM3335 in Huntington`s disease (HD) patients with chorea movements.

Summary

EudraCT number	2018-000203-16
Trial protocol	ES
Global end of trial date	22 August 2019

Results information

Result version number	v1 (current)
This version publication date	06 July 2022
First version publication date	06 July 2022

Trial information

Trial identification

Sponsor protocol code	SOMCT02

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03575676
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	SOM Innovation Biotech SA
Sponsor organisation address	Baldiri Reixac, 4, Barcelona, Spain, 08028
Public contact	Clinical Project Leader, SOM Biotech, 34 934020150, ferre@sombiotech.com
Scientific contact	Clinical Project Leader, SOM Biotech, 34 934020150, ferre@sombiotech.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	22 October 2019
Is this the analysis of the primary completion data?	Yes
Primary completion date	22 August 2019
Global end of trial reached?	Yes
Global end of trial date	22 August 2019
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To determine whether SOM3355 reduces chorea movements associated with Huntington's Disease.

Protection of trial subjects:

Inclusion and exclusion criteria were carefully selected to include only those patients that could benefit from the investigational medicinal product without taking any risk related to their concomitant pathologies and medications. Subject withdrawal criteria were also defined so the investigator may discontinue any patient from the study if he/she considers it necessary for any reason.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	08 August 2018
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Spain: 32
Worldwide total number of subjects	32
EEA total number of subjects	32

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	30
From 65 to 84 years	2
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Patients were recruited between August 2018 and February 2019 at four sites in Spain.

Pre-assignment

Screening details:

The main inclusion criteria were having a Unified Huntington's Disease Rating Scale (UHDRS) Total Maximal Chorea (TMC) score ≥8 and Total Functional Capacity (TFC) score ≥4.
The exclusion criteria were being co-administered VMAT2 inhibitors, antihypertensive medications, monoamine oxidase inhibitors, or typical neuroleptics.

Period 1

Period 1 title	Arm A and Arm B in cross-over (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Carer

Blinding implementation details:

Study drug was manufactured to be blind.

Arms

Are arms mutually exclusive?	Yes
Arm title	Arm A (sequence active drug-placebo)

Arm description:

Administration of SOM3355 100mg BID for 6 weeks, SOM3355 200mg BID for 6 weeks, SOM3355 100mg BID for 6 weeks, and placebo BID for 6 weeks.

Arm type	Experimental
Investigational medicinal product name	SOM3355 100mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule, hard
Routes of administration	Oral use

Dosage and administration details:

SOM3355 100mg capsules were orally administered twice daily (BID).

Investigational medicinal product name	SOM3355 200mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule, hard
Routes of administration	Oral use

Dosage and administration details:

SOM3355 200mg capsules were orally administered twice daily (BID).

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule, hard
Routes of administration	Ocular use

Dosage and administration details:

Placebo capsules were orally administered twice daily (BID).

Arm title	Arm B (sequence placebo-active drug)

Arm description:

Administration of placebo BID for 6 weeks, SOM3355 100mg BID for 6 weeks, SOM3355 200mg BID for 6 weeks, and SOM3355 100mg BID for 6 weeks.

Arm type	Experimental
Investigational medicinal product name	SOM3355 100mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule, hard
Routes of administration	Oral use

Dosage and administration details:

SOM3355 100mg capsules were orally administered twice daily (BID).

Investigational medicinal product name	SOM3355 200mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule, hard
Routes of administration	Oral use

Dosage and administration details:

SOM3355 200mg capsules were orally administered twice daily (BID).

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule, hard
Routes of administration	Ocular use

Dosage and administration details:

Placebo capsules were orally administered twice daily (BID).

Number of subjects in period 1	Arm A (sequence active drug-placebo)	Arm B (sequence placebo-active drug)
Started	16	16
Completed	14	13
Not completed	2	3
Sponsor's decision	-	1
Adverse event, non-fatal	1	2
Non-compliance with study drug	1	-

Baseline characteristics

Reporting groups	
Reporting group title	Arm A and Arm B in cross-over
Reporting group description:	
Safety Population (SP): All patients who received at least one dose of study treatment.	

Reporting group values	Arm A and Arm B in cross-over	Total	
Number of subjects	32	32	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	30	30	
From 65-84 years	2	2	
85 years and over	0	0	
Age continuous			
Units: years			
arithmetic mean	49.0		
standard deviation	± 9.7	-	
Gender categorical			
Units: Subjects			
Female	19	19	
Male	13	13	

End points

End points reporting groups

Reporting group title	Arm A (sequence active drug-placebo)
Reporting group description:	
Administration of SOM3355 100mg BID for 6 weeks, SOM3355 200mg BID for 6 weeks, SOM3355 100mg BID for 6 weeks, and placebo BID for 6 weeks.	
Reporting group title	Arm B (sequence placebo-active drug)
Reporting group description:	
Administration of placebo BID for 6 weeks, SOM3355 100mg BID for 6 weeks, SOM3355 200mg BID for 6 weeks, and SOM3355 100mg BID for 6 weeks.	
Subject analysis set title	Per Protocol Population
Subject analysis set type	Per protocol
Subject analysis set description:	
Per Protocol (PP) population consisted of all randomized patients who completed V0-V3 study visits and did not have major protocol deviations.	

Primary: Primary endpoint

End point title	Primary endpoint
End point description:	
Improvement in any active drug period in Total Maximal Chorea (TMC) score of at least 2 points compared with placebo period	
End point type	Primary
End point timeframe:	
6 weeks	

End point values	Arm A (sequence active drug-placebo)	Arm B (sequence placebo-active drug)	Per Protocol Population	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	14	14	28	
Units: % subjects reaching the primary endpoint				
number (not applicable)	57.1	57.1	57.1	

Statistical analyses

Statistical analysis title	Primary efficacy analysis
Comparison groups	Arm A (sequence active drug-placebo) v Arm B (sequence placebo-active drug) v Per Protocol Population
Number of subjects included in analysis	56
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.05
Method	Mixed models analysis
Parameter estimate	Mean difference (final values)

Confidence interval	
level	95 %
sides	2-sided
Variability estimate	Standard deviation

Adverse events

Adverse events information	
Timeframe for reporting adverse events: 27 weeks	
Assessment type	Systematic
Dictionary used	
Dictionary name	MedDRA
Dictionary version	22.1
Reporting groups	
Reporting group title	Safety Population
Reporting group description: All patients who had received at least one dose of study treatment were included in the safety population (SP).	

Serious adverse events	Safety Population		
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 32 (3.13%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events			
Psychiatric disorders			
Delirium			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 32 (3.13%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Safety Population		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	24 / 32 (75.00%)		
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	5 / 32 (15.63%)		
occurrences (all)	7		
Hand fracture			

subjects affected / exposed occurrences (all)	2 / 32 (6.25%) 2		
Vascular disorders Hypotension subjects affected / exposed occurrences (all)	 4 / 32 (12.50%) 4		
Cardiac disorders Bradycardia subjects affected / exposed occurrences (all)	 5 / 32 (15.63%) 5		
Nervous system disorders Dizziness subjects affected / exposed occurrences (all) Hypokinesia subjects affected / exposed occurrences (all)	 3 / 32 (9.38%) 3 2 / 32 (6.25%) 2		
Gastrointestinal disorders Diarrhoea subjects affected / exposed occurrences (all)	 2 / 32 (6.25%) 2		
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	 2 / 32 (6.25%) 2		
Psychiatric disorders Insomnia subjects affected / exposed occurrences (all) Irritability subjects affected / exposed occurrences (all)	 5 / 32 (15.63%) 5 2 / 32 (6.25%) 2		
Infections and infestations Gastroenteritis subjects affected / exposed occurrences (all) Influenza	 2 / 32 (6.25%) 2 		

subjects affected / exposed occurrences (all)	2 / 32 (6.25%) 2		
Metabolism and nutrition disorders Increased appetite subjects affected / exposed occurrences (all)	 2 / 32 (6.25%) 2		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported